Health, ​R​​​esilience and ​Prosperity: Why ​Immunization ​Matters

Why It Matters

Treating immunisation as a resilience pillar unlocks health‑system efficiency, protects the workforce, and creates fiscal space in an era of constrained public finances. The shift also strengthens Europe’s strategic autonomy in vaccine innovation and supply.

Key Takeaways

• Immunization reframed as strategic resilience pillar across health, economy, society
• EU links vaccines to cancer prevention, cardiovascular risk reduction, and AMR mitigation
• Irish RSV program cut cases 65% and hospitalizations 76% with 80% uptake
• Adult vaccine programs can yield up to 19‑fold return on investment
• EU vaccine spending under 0.5% of health budgets, considered underinvested

Pulse Analysis

Europe’s demographic trends—aging populations, rising chronic disease burden, and climate‑driven health threats—are forcing policymakers to view immunisation through a broader lens. By preventing the initial infection cascade, vaccines reduce downstream complications such as secondary bacterial infections, antibiotic overuse, and even vaccine‑preventable cancers like HPV‑related cervical disease. This holistic approach aligns with the European Commission’s recent recommendations that embed vaccination in cancer, cardiovascular, and antimicrobial‑resistance strategies, positioning it as a core component of health‑system preparedness.

The economic case for this shift is compelling. Data from Ireland’s first national RSV immunisation season demonstrate that high uptake can slash disease incidence by two‑thirds and free hundreds of hospital beds in a single winter. Similar gains translate into fewer sick‑days, lower caregiver burden, and preserved productivity across the EU. Studies estimate adult immunisation programmes can deliver up to a 19‑times return on investment, offsetting hospital costs, reducing antibiotic prescriptions, and generating fiscal space for other health priorities.

Despite these benefits, most EU member states allocate less than half a percent of their health‑care budgets to vaccination, a stark underinvestment given the proven ROI. Strengthening the vaccine ecosystem—from R&D and manufacturing to distribution—requires sustained, predictable funding and coordinated EU‑level policies. By treating immunisation as a strategic asset, Europe can safeguard public health, bolster economic resilience, and reinforce its competitive edge in the global pharmaceutical landscape.